Dallas, Texas 05/20/2014 (FINANCIALSTRENDS) – Express Scripts Holding Company (NASDAQ:ESRX) recently updated its full fiscal FY14 earnings guidance with an adjusted EPS outlook of $4.82 to $4.94 for the period. This is pretty much is line with earnings of $4.87 per share anticipated by the Thomson Reuters consensus estimate. The company keeps an adjusted EBITDA outlook same as previously announced at $6.775 billion to $6.975 billion for FY14. The company anticipates adjusted EBITDA for FY14 per adjusted claim to be in range of $5.20 to $5.30, reports theflyonthewall.com.
Recently, equity analysts at BMO Capital Markets downgraded their price target for the stock of Express Scripts Holding Company (NASDAQ:ESRX) to $74 from their previously set price target of $77. Investment analysts at FBR Capital Markets reaffirmed an “outperform” rating for the stock with a price objective of $82 per share. Separately, analysts at Deutsche Bank continued their “hold” rating on the stock in research note released at the start of this month. They now maintain a $76 price objective on the stock. Investment analysts at Leerink Swann also maintained their “outperform” rating for the stock and they now have a price target of $80 per share.
The stock of Express Scripts Holding Company (NASDAQ:ESRX) has been assigned a “hold” rating by three equity research analysts; and a “buy” rating by seventeen equity research analysts. The stock of the company currently has an average rating of “buy” with an average price objective of $79.10 which suggests potential upside of 14.85% from its previous closing.
Express Scripts Holding offers a range of PBM (Pharmacy Benefit Management) services mainly in the U.S. and Canada. Besides PBM, the company also operates in Other Business Operations. Yesterday, its stock closed at $68.87, gaining 0.22% from its previous close. Its 52 week price ranges between $59.20 and $79.37.